Infectious Period

The infectious period is the span of time during which an infected individual can transmit a pathogen to others.

It begins when the person starts shedding the virus, bacteria, or other agent at levels capable of causing infection in others, and ends when that shedding declines below a transmissible level.

The infectious period may or may not overlap with the time when a person has symptoms.

Why the infectious period matters

Understanding the infectious period is essential for designing effective public health interventions.

How it informs public health strategies

It informs decisions about how long people need to isolate, when they are most likely to spread the infection, and which contacts might be at risk.

Key uses of infectious period data

• Determining isolation duration
• Identifying high-risk exposure windows
• Timing testing and contact tracing
• Administering post-exposure prophylaxis
• Evaluating when to lift precautions
• Guiding return-to-work or school decisions

Settings where timing of infectiousness is critical

• Hospitals and clinics
• Schools and childcare centers
• Long-term care facilities
• Correctional facilities
• Congregate shelters

In these environments, accurately identifying the infectious period helps prevent secondary transmission.

Diseases with short infectious periods

• Influenza
• Norovirus
• COVID-19 (typically acute phase)

Diseases with long infectious periods

• HIV
• Hepatitis B
• Tuberculosis

Case study: COVID-19 and infectious timing

Presymptomatic and early symptomatic spread

When it first emerged and people had no prior immunity from either infection or vaccination, COVID-19 patients were infectious from about two days before symptom onset through the first five days of illness.

• Viral shedding began before symptoms appear
• Transmission risk highest early in illness
• Later stages of illness less infectious, especially in mild cases

Implications for control strategies

Presymptomatic spread limited the effectiveness of symptom-based screening alone.

• Widespread testing needed to catch early infections
• Masking and distancing used to reduce silent spread
• Rapid isolation essential even for mild symptoms

Role of variant, immunity, and vaccination

The duration and timing of infectiousness began to change over time, based on variants and individual immunity from infection and/or vacination.

• Some variants cause higher viral loads for longer periods
• Vaccinated individuals often have shorter infectious periods
• Immunocompromised people may shed virus longer

Impact on contact tracing and testing

Knowing when someone was likely infectious improves identification of who may have been exposed.

• Supports more accurate contact tracing timelines
• Informs when to test exposed individuals
• Helps avoid unnecessary quarantine for low-risk contacts

Adapting isolation guidelines over time

Guidance evolved to reflect new evidence on infectious duration and transmission risk. Asymptomatic transmission is less common now that people have pre-existing immunity. Patients tend to generate an immune response early, prompting symptoms. They tend to be infectious only after several days of infection and symptoms.

Clinical and public health applications

• Deciding when to release patients from isolation
• Advising close contacts on testing and precautions
• Implementing cohorting strategies in care facilities

Limitations and considerations

• Infectious period can vary widely between individuals
• Viral detection by PCR tests doesn’t always mean transmissibility
• Antigen tests perform well at determining whether a patient is likely to be infectious to others
• More data needed for many emerging infections

Improving outbreak control with better timing

Refining interventions based on infectiousness

• Tailor isolation duration to disease and risk profile
• Incorporate rapid testing to guide release decisions
• Use viral load or antigen tests to assess infectiousness
• Develop models that predict shedding duration by individual characteristics
• Communicate risk clearly to support adherence